返回 Agenda
Session 2C: Cardiovascular/Metabolic Diseases
Session Chair(s)
Peter Wijngaard, PhD
Executive Vice President and Chief Development Officer
The Medicines Company, United States
Review progress made in the clinical development of RNA therapeutics in the cardiovascular and metabolic therapeutic areas. The targets and applications range from Factor XI antagonism in the coagulation pathway using antisense oligonucleotides to the inhibition of PCSK9 synthesis via RNA interference and GalNAc conjugation to reduce cardiovascular risk factors.
Learning Objective : At the conclusion of this session, participants should be able to:
- Identify accomplishments and challenges in the clinical development of oligonucleotide-based therapeutic drugs for Cardiovascular/Metabolic diseases
- Recognize the achievements made in the field to date and be able to share the therapeutic potential with potential customers (patients, prescribers, payors) that oligonucleotides possess in (large) cardiovascular/metabolic indications
Speaker(s)
Session Co-Chair
Elena Braithwaite, PhD
FDA, United States
Toxicologist
Antisense Reduction of FXI for Thromboprophylaxis: A Novel Therapeutic Approach
Sanjay Bhanot, MD, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, Metabolic Diseases, Research & Development
Volanesorsen: Targeting ApoC-III for Treatment of Patients with Familial Chylomicronemia Syndrome (FCS)
Louis St.L. O'Dea
AKCEA Therapeutics, United States
Executive Vice President, Chief Medical Officer and Head, Regulatory Affairs
PCSK9 Synthesis Inhibition: siRNA Therapeutic for Large Indications
Peter Wijngaard, PhD
The Medicines Company, United States
Executive Vice President and Chief Development Officer
Panel Discussion
All Session Speakers, United States